{"id":103171,"date":"2023-09-21T16:46:47","date_gmt":"2023-09-21T16:46:47","guid":{"rendered":"https:\/\/dailytalks.org\/?p=103171"},"modified":"2023-09-21T16:46:47","modified_gmt":"2023-09-21T16:46:47","slug":"canariabio-announces-enrollment-completion-of-phase-2-study-of-oregovomab-in-combination-with-niraparib-in-the-treatment-of-recurrent-ovarian-cancer","status":"publish","type":"post","link":"https:\/\/dailytalks.org\/?p=103171","title":{"rendered":"CanariaBio Announces Enrollment Completion of Phase 2 Study of Oregovomab in Combination with Niraparib in the Treatment of Recurrent Ovarian Cancer"},"content":{"rendered":"<p>SEOUL, S.KOREA, Aug 8, 2023 &#8211; (JCN Newswire) &#8211;  CanariaBio, a KOSDAQ-listed and a leading late-stage biotechnology company, announces the successful enrollment completion of a Phase 2 study of Oregovomab in combination with niraparib, GSK&#8217;s poly (ADP-ribose) polymerase (PARP) inhibitor, for treatment of patients with platinum-sensitive recurrent ovarian cancer.This trial&#8230;<br \/><a href=\"https:\/\/www.jcnnewswire.com\/pressrelease\/85721\/3\/\" class=\"button purchase\" rel=\"nofollow noopener\" target=\"_blank\">Read More<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>SEOUL, S.KOREA, Aug 8, 2023 &#8211; (JCN Newswire) &#8211; CanariaBio, a KOSDAQ-listed and a leading<\/p>\n","protected":false},"author":1,"featured_media":103172,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[35],"tags":[],"class_list":["post-103171","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-tech"],"featured_image_urls":{"full":["https:\/\/dailytalks.org\/wp-content\/uploads\/2023\/09\/103171-canariabio-announces-enrollment-completion-of-phase-2-study-of-oregovomab-in-combination-with-niraparib-in-the-treatment-of-recurrent-ovarian-cancer.jpg",220,44,false],"thumbnail":["https:\/\/dailytalks.org\/wp-content\/uploads\/2023\/09\/103171-canariabio-announces-enrollment-completion-of-phase-2-study-of-oregovomab-in-combination-with-niraparib-in-the-treatment-of-recurrent-ovarian-cancer-150x44.jpg",150,44,true],"medium":["https:\/\/dailytalks.org\/wp-content\/uploads\/2023\/09\/103171-canariabio-announces-enrollment-completion-of-phase-2-study-of-oregovomab-in-combination-with-niraparib-in-the-treatment-of-recurrent-ovarian-cancer.jpg",220,44,false],"medium_large":["https:\/\/dailytalks.org\/wp-content\/uploads\/2023\/09\/103171-canariabio-announces-enrollment-completion-of-phase-2-study-of-oregovomab-in-combination-with-niraparib-in-the-treatment-of-recurrent-ovarian-cancer.jpg",220,44,false],"large":["https:\/\/dailytalks.org\/wp-content\/uploads\/2023\/09\/103171-canariabio-announces-enrollment-completion-of-phase-2-study-of-oregovomab-in-combination-with-niraparib-in-the-treatment-of-recurrent-ovarian-cancer.jpg",220,44,false],"1536x1536":["https:\/\/dailytalks.org\/wp-content\/uploads\/2023\/09\/103171-canariabio-announces-enrollment-completion-of-phase-2-study-of-oregovomab-in-combination-with-niraparib-in-the-treatment-of-recurrent-ovarian-cancer.jpg",220,44,false],"2048x2048":["https:\/\/dailytalks.org\/wp-content\/uploads\/2023\/09\/103171-canariabio-announces-enrollment-completion-of-phase-2-study-of-oregovomab-in-combination-with-niraparib-in-the-treatment-of-recurrent-ovarian-cancer.jpg",220,44,false],"chromenews-featured":["https:\/\/dailytalks.org\/wp-content\/uploads\/2023\/09\/103171-canariabio-announces-enrollment-completion-of-phase-2-study-of-oregovomab-in-combination-with-niraparib-in-the-treatment-of-recurrent-ovarian-cancer.jpg",220,44,false],"chromenews-large":["https:\/\/dailytalks.org\/wp-content\/uploads\/2023\/09\/103171-canariabio-announces-enrollment-completion-of-phase-2-study-of-oregovomab-in-combination-with-niraparib-in-the-treatment-of-recurrent-ovarian-cancer.jpg",220,44,false],"chromenews-medium":["https:\/\/dailytalks.org\/wp-content\/uploads\/2023\/09\/103171-canariabio-announces-enrollment-completion-of-phase-2-study-of-oregovomab-in-combination-with-niraparib-in-the-treatment-of-recurrent-ovarian-cancer.jpg",220,44,false]},"author_info":{"display_name":"Jonathan Jeriah","author_link":"https:\/\/dailytalks.org\/?author=1"},"category_info":"<a href=\"https:\/\/dailytalks.org\/?cat=35\" rel=\"category\">Tech<\/a>","tag_info":"Tech","comment_count":"0","_links":{"self":[{"href":"https:\/\/dailytalks.org\/index.php?rest_route=\/wp\/v2\/posts\/103171","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/dailytalks.org\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/dailytalks.org\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/dailytalks.org\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/dailytalks.org\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=103171"}],"version-history":[{"count":0,"href":"https:\/\/dailytalks.org\/index.php?rest_route=\/wp\/v2\/posts\/103171\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/dailytalks.org\/index.php?rest_route=\/wp\/v2\/media\/103172"}],"wp:attachment":[{"href":"https:\/\/dailytalks.org\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=103171"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/dailytalks.org\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=103171"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/dailytalks.org\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=103171"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}